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1. Introduction {#s0005}
===============

Osteoarthritis (OA) is the most common type of arthritis affecting more than half of people over the age of 65 and is more prevalent in women (18%) than in men (9.6%) after menopause ([@b0205]). It is a chronic, degenerative joint disorder affecting millions of people worldwide ([@b0015]). OA is considered as one of the most common causes of disability affecting the joints of the knee, hips and hands. It can be classified into two different forms namely: primary and secondary OA. Primary or idiopathic OA is gene dependent while secondary or post traumatic OA occurs mainly after a traumatic event ([@b0205]). Although primary and secondary OA are caused by different factors, they both result in the same abnormalities, a degenerative phenomenon complicated by inflammatory reactions ([@b0240]). OA is a complex disease causing a change in the tissue homeostasis of articular cartilage and the subchondral bone. The common features of OA include loss of cartilage, narrowing of joint spaces, hypertrophic bone changes and the formation of osteophyte ([@b0015]). The latter refers to the overgrowth of the bone and cartilage occurring at the joint margins. The stiffening of the subchondral bone causes the bone to be less able to absorb impact loads and thereby leading to increased stress in the cartilage ([@b0165]). The primary cause of OA remains largely unknown and various factors can play a role in the development of OA ([Fig. 1](#f0005){ref-type="fig"}). The development of knee arthritis has been strongly associated with excess weight, obesity, gender and previous knee injury. Diabetes is also associated with the progression of knee OA ([@b0205]). The signs and symptoms of OA usually include: pain, stiffness of the joints, muscle weakness and swelling of the knee.Figure 1An illustration of the risk factors that are involved in osteoarthritis (adapted from [@b0015]).

Articular cartilage is a specialized connective tissue covering the joint surfaces that has no nerve supply and is therefore susceptible to early injuries ([@b0230]). It is a hyaline cartilage characterized by a compact collagen network and extracellular matrix made up of proteoglycan, and is highly resistant to mechanical loads ([@b0255]). Articular cartilage is avascular, aneural and alymphatic, and it is constituted by one cell type, the chondrocytes. Articular cartilage has poor repair properties due to a relatively low number of cells in the tissue, decreased metabolic rate, and matrix fibers that restrict the division of chondrocytes and their migration in the articular cartilage. The treatment of injured articular cartilage poses a major challenge to orthopedic surgeons because of its limited self-healing capacity. To date, there is no universally accepted successful treatment for injured or damaged articular cartilage ([@b0230]).

Ozone (O~3~) is a colorless gas with an acrid odor and was first discovered in 1848 ([@b0065]). The basic function of O~3~ is to protect living organisms from the harmful effects of UV radiation. It occurs at a concentration of less than 20 μg/m^3^ at the earth's surface which is a concentration that is compatible with life ([@b0080]). O~3~ was used for treating gaseous post-traumatic gangrene, burns, infected wounds and fistulas in German soldiers during World War I ([@b0115]). Since its discovery, O~3~ has been used as a therapeutic agent to treat different diseases. It exerts its effects, by preparing the host to undergo physiopathological events mediated by ROS ([@b0150]). O~3~ possess both virucidal and bactericidal properties, and can be used for disinfection, sterilization and destruction of malignant cells ([@b0075]). Hydrogen peroxide (H~2~O~2~) is produced during O~3~ therapy resulting from oxidative stress and lipid oxidation which mediates the biological effects of O~3~ therapy by acting as second messenger ([@b0150]). Repeated exposure to O~3~ therapy may cause resistance against oxidative stress via inducing the antioxidative system.

O~3~ therapy activates the enzymes that are responsible for protecting the body against processes linked to the overproduction of superoxides. During O~3~ therapy, there is stimulation of transmembranous flow of oxygen and the induction of enzymes such as superoxide dismutase, peroxidases or catalases and the oxygen utilization in the mitochondrial respiratory chain becomes more effective ([@b0175]). Superoxide is the most crucial radical, playing a key role in biological regulation ([@b0150]). In the last decades a number of orthopedics in Europe have used ozone to treat acute and chronic knee arthritis and the results show rapid pain relief, disappearance of edema, decongestion and increased mobility. Unfortunately there are no experimental studies on the mechanism of action of ozone in the knee arthritis, and there is a large variability in terms of side of injection, volume and concentration of ozone ([@b0045]).

2. History of ozone (O~3~) therapy {#s0010}
==================================

Van Mauren, first discovered the distinctive odor of O~3~ in 1785. The actual gas was later discovered by a German Chemist Christian Friedrich Schonbein at the University of Basel in Switzerland in 1840, when working with a voltaic pile in the presence of oxygen ([@b0010]). Friedrich noticed the emergence of a gas with an electric and pungent smell, and named it ozone, which is derived from the Greek word for smell, because of its pungent smell ([@b0030]). In 1860, Jacques-Louis Soret, a Swiss chemist then demonstrated that the ozone molecule was made up of three atoms of oxygen ([@b0010]). The disinfecting and oxidating properties of O~3~ were first demonstrated in the laboratory of an Irish chemist, Thomas Andrews ([@b0030]). O~3~ was used for the first time to disinfect operating rooms in a hospital in 1856, and in 1860, the first ozone water treatment plant was built in Monaco to disinfect water ([@b0010]). Werner von Siemens practically applied the concept that O~3~ derives from oxygen when an electric discharge is generated by a voltaic arc. Siemens is the inventor of the super induction tube (Siemens's tube), consisting of two interposed electrode plates set at high voltage, which could generate O~3~ in the presence of oxygen ([@b0030]). An outbreak of cholera in Hamburg which killed thirty thousand people led to the construction of the first waterworks to use O~3~ in Germany in 1901 ([@b0010]). To date, the disinfecting properties of O~3~ are well known and there are more than three thousand municipal O~3~ water treatment facilities in the world ([@b0030]).

The first medical application of O~3~ was in the treatment of post traumatic gangrene in German soldiers during the first world war from 1914 to 1918 ([@b0030]). O~3~ was also used to prevent infection in local medical procedures and to control wound infections because of its prophylactic properties during World War I ([@b0185]). The invention of a reliable O~3~ generator by a physicist, Joachim Hansler, was a major breakthrough in the use of O~3~ for medical applications. In the late 1980 s, there were reports that Germans were successfully treating HIV patients with ozonated autohemotherapy (O~3~-AHT). At that time, there was no pharmacological treatment of HIV, thus the Canadian government approved the testing of O~3~-AHT for its safety and efficacy in treating AIDS patients ([@b0080]). O~3~ was effective at disinfecting extracorporeal blood samples of HIV, but was ineffective when applied *in vivo* ([@b0080]).

3. Treatment of injured articular cartilage {#s0015}
===========================================

Injured or damaged articular cartilage remains one of the most difficult tissues to treat. There are several techniques that have been developed in the past to treat damaged articular cartilage. These include: arthroscopic lavage and debridement, bone marrow stimulation technique, osteochondral autografting (OCG), autologous chondrocyte implantation (ACI) and now recently mesenchymal stem cells (MSCs) are used in treating injured articular cartilage.

3.1. Arthroscopic lavage and debridement {#s0020}
----------------------------------------

Arthroscopic lavage washes out loose cartilage, inflammatory mediators and collagen debris that can be present in the synovium causing synovitis and effusion ([@b0085]). The debridement of cartilage (chondroplasty) aims to remove loose chondral flaps and fibrillated articular cartilage to a smoother surface while avoiding any damage to the healthy surrounding cartilage ([@b0230]). Debridement chondroplasty can be done using several techniques including curettage, and mechanical debridement with a shaver; however this technique does not leave smooth cartilage and may cause further cartilage breakdown ([@b0085]). Furthermore, thermal debridement uses radiofrequency energy and this technique causes chondrocyte death and matrix degeneration ([@b0085]).

3.2. Bone marrow stimulation technique {#s0025}
--------------------------------------

This technique exposes the chondral defect to the bone marrow, thereby creating an environment which causes fibrocartilage healing. The bone marrow stimulation technique includes microfracture and subchondral drilling of cartilage ([@b0230]). The drilling technique was developed by Pridie in 1959 in order to bring the pluripotent stem cells into a chondral defect. The subchondral bone is drilled with a high speed drill through the trabecular bone and blood is allowed to perfuse into the defect resulting in the formation of a blood clot, thereby initiating the repairing of the defect ([@b0085]). The repaired cartilage contains a mixture of hyaline and fibrocartilage. Subchondral drilling causes thermal necrosis which is a major setback of this technique. To reduce thermal damage caused by drilling, Steadman and Rokey, developed the microfracture technique in the late 1980 s. This technique allows the accurate debridement of all unstable and damaged articular cartilage, down to the subchondral bone plate while maintaining a stable perpendicular edge of healthy cartilage ([@b0260]). Multiple holes in the defect are made 3--4 mm apart using an arthroscopic awl. Following the making of a microfracture, the defect is filled with fibrin clot, which is an optimal environment for the pluripotential marrow cells to differentiate into stable cells ([@b0265]). Histological analysis after a microfracture repair shows that a hybrid of hyaline and fibrocartilage dominates the site of defect ([@b0085]).

3.3. Osteochondral autografting {#s0030}
-------------------------------

OCG is useful in small lesions with subchondral bone loss ([@b0230]). OCG involves the harvesting of multiple individual osteochondral plugs from the donor site, usually from a non-weight bearing area of the knee. Using a press fit technique; the grafts from the donor site are inserted into the lesion in a mosaic like fashion (mosaicplasty) to replace damaged or missing articular cartilage and to supply the chondral lesion with islands of viable and immediately functional hyaline cartilage ([@b0195]). This results in the formation of a surface consisting of the transplanted hyaline cartilage and fibrocartilage from the abrasion arthroplasty. The fibrocartilage acts a grout between the individual grafts. The disadvantage of OCG is donor site morbidity, but there are advantages in this being a one-step procedure with consistent survival of the hyaline cartilage ([@b0230]).

3.4. Autologous chondrocyte implantation (ACI) {#s0035}
----------------------------------------------

ACI was first conducted by Peterson and colleagues in Gothenburg in 1987 and was the first application of cell engineering in orthopedic surgery ([@b0260]). In ACI, a healthy cartilage is obtained from the affected knee and chondrocytes are cultured in a suitable environment ([@b0230]). After a few weeks, the cells are then reimplanted into the defect underneath a patch of periosteum ([@b0260]). Newer generations of ACI are available and this includes, characterized chondrocyte implantation (CCI) and matrix induced ACI (MACI) which involve the placing of cells underneath the scaffolds thereby reducing the complications of periosteal hypertrophy seen in ACI ([@b0230]).

3.5. Mesenchymal stem cells (MSCs) therapy {#s0040}
------------------------------------------

Currently, the most innovative approach to investigate and treat joint disorders is the use of MSCs. MSCs are multipotent stem cells that have the ability to migrate and engraft onto multiple musculoskeletal tissues, especially sites of injury and undergo site specific differentiation ([@b0060]). The chondrogenic differentiation potential of MSCs has made them a hopeful candidate progenitor cell source for cartilage tissue engineering ([@b0220]). MSCs can be isolated from many types of tissues, such as adipose tissue, bone marrow, umbilical cord blood, placenta, synovium, periosteum and muscle. MSCs can secrete a broad spectrum of bioactive molecules with regenerative and/or immunoregulatory activities ([@b0050]). MSCs therapy allows the repairing of both the cartilage and bone, and results in improved remodeling and integration with the host surface zone ([@b0090]). In general, MSCs combined with three dimensional scaffolds and growth factors, are implanted into the cartilage defect, and result in the repairing of the cartilage defect.

4. Reactive oxygen species (ROS) and osteoarthritis (OA) {#s0045}
========================================================

ROS are the most abundant free radicals in the biological system and are continuously formed as normal by products of cellular metabolism ([@b0225]). When the oxidant level does not exceed the reducing capabilities of cells, ROS are vital for physiological processes such as cell differentiation, protein phosphorylation, transcription factor activation, apoptosis, cell immunity, steroidogenesis and cell defense against microorganisms ([@b0190]). Under normal conditions, a delicate balance exists between free radical production and their scavenging mechanism ([@b0065]). In pathological conditions, there is an excessive generation of ROS which can harm cell functionality because it damages cellular lipids, proteins and DNA. ROS modify proteins by the oxidation of amino acids resulting in impaired biological activity, altered protein structure and the accumulation of damaged proteins in tissue ([@b0130]). Oxidized molecules can react with non-oxidized molecules resulting in the formation of more oxidized molecules which may further damage the tissue ([@b0130]). Oxidative stress may eventually result in cell death and the release of cellular contents into the surrounding environment.

The development and progression of OA, as with other degenerative diseases is associated with the continuous exposure to oxidants ([@b0095]). In normal physiological conditions, chondrocytes live in conditions with low oxygen supply and some of their metabolic functions require oxygen which is supplied by the synovial fluid ([@b0130]). Chondrocytes thus have a metabolism adapted to anaerobic conditions, and in response to changes in partial oxygen pressure, mechanical stress, inflammatory and immunomodulatory mediators, chondrocytes produce increased levels of ROS ([@b0130]). The main ROS produced by chondrocytes are nitric oxide (NO) and superoxide anion (O~2~^−^) that can result in the formation of derivative radicals such as H~2~O~2~ and peroxynitrite (ONOO^−^) ([@b0135]). The ROS produced by chondrocytes can damage the cartilage and synovial fluid by reducing its viscosity ([@b0180]) ([Fig. 2](#f0010){ref-type="fig"}). The production of NO is stimulated by tumor necrosis factor (TNF)-β, interleukin (IL)-β, interferon (IFN)-γ and lipopolysaccharides and inhibited by IL-4, IL-10, IL-13 and transforming growth factors (TGF)-β ([@b0125], [@b0040]). Excessive production of NO contributes to the pathogenesis of chronic arthritis ([@b0270]). NO can also interfere with chondrocyte function resulting in the loss of cartilage matrix by apoptosis induction, type 2 collagen synthesis inhibition and matrix metalloproteinase activation ([@b0210], [@b0205]). Besides ROS itself, lipid peroxidation products may also result in the formation of reactive aldehydes and lead to inflammations ([@b0275]). These lipid peroxidation products have longer biological half-lives than free radicals and can diffuse from the site of formation to reach a distant target and induce cellular injury ([@b0070]).Figure 2An illustration of a healthy joint cushioned by articular cartilage and an osteoarthritic joint where there articular cartilage is completely damaged and the bone ends are exposed to each other.

5. Ozone (O~3~) therapy in osteoarthritis (OA) {#s0050}
==============================================

O~3~ therapy has been widely used in the treatment of OA ([@b0110]). The intra articular injection of O~3~ has been suggested for the treatment of osteoarthritis and has yielded positive results ([@b0245]). [@b0065] showed that direct injection of ozone into the superior joint space of patients with internal derangement of the temporomandibular joint yielded a good clinical outcome. The application of O~3~ seems to be empirical and there are limited studies showing the histological and biochemical evidence for the effects of its use ([@b0145]). O~3~ acts as a bioregulator by releasing factors from endothelial cells and normalizing the cellular redox balance when it comes into contact with a biological fluid ([@b0145]). O~3~ can change the levels of cytokines such as interleukin 8, TNF-α, transforming factor beta1 (TGF beta1) and platelet derived growth factor (PDGF) ([@b0215], [@b0035]). When O~3~ is administered intravenously, it dissolves in biological fluids such as plasma, urine and lymph, where it reacts with polyunsaturated fatty acids, antioxidants, reduced glutathione and albumin ([@b0120]). All of these compounds can act as an electron donor and undergo oxidation. O~3~ causes oxidation of these compounds resulting in the formation of H~2~O~2~ and lipid oxidation products (LOPs). The following reaction shows the simultaneous formation of one mole of H~2~O~2~ included among ROS and two moles of lipid oxidation products (LOPs) ([@b0025]).$$\left. \text{RCHCH}\text{R}^{\prime} + \text{O}_{3} + \text{H}_{2}\text{O}\rightarrow\text{RCHO} + \text{R}^{\prime}\text{CHO} + \text{H}_{2}\text{O}_{2} \right.$$

H~2~O~2~ is able to act as an ozone messenger for initiating therapeutic and biological effects ([@b0120]). Excessive amounts of H~2~O~2~ can be detrimental to cells while at physiological amounts H~2~O~2~ acts as a regulator of signal transduction and is an important mediator of the host defense and immune responses ([@b0235]). H~2~O~2~ acts immediately and disappears (early and short acting messengers) while LOPs remains in the circulation and distributes throughout the tissues and thus becoming late and long lasting messengers ([@b0025]). This process leads to the stimulation of the innate immune system and helps the cells to survive injury. O~3~ therapy stimulates the production of interferon and interleukins in the body and initiates the production of antioxidant enzymes ([@b0025]). The immune system can also be stimulated by activating neutrophils and stimulating the release of cytokines. O~3~ increases the levels of TGFβ which is important in tissue remodeling.

O~3~ therapy reduces TNF-α concentrations, which is a proinflammatory cytokine, activating the nuclear factor-κB (NFκB) pathway, leading to a downstream cascade of other proinflammatory cytokines giving rise to a vicious cycle which perpetuates the chronic inflammatory process ([@b0155], [@b0270]). TNF-α is strongly associated with joint and bone injury ([@b0270]). This cytokine is also known to increase the mitochondrial ROS production and inhibition of TNF-α may decrease ROS production in OA, thereby causing the improvement and prevention of joint erosion. The inhibition of TNF-α may break the noxious NFκB pathway causing a reduction of the inflammation. ROS can function as a second messenger to activate NFκB, which co-ordinates the expression of a wide range of genes involved in the inflammatory response. The efficacy of O~3~ therapy is not only through the actions of cytokines, O~3~ also has the ability to re-establish the cellular redox homeostasis ([@b0270]). O~3~ can protect against overproduction of NO and this is likely because of ozone's action on NFκB, since inducible nitric oxide synthase (iNOS) is regulated at the transcriptional level by NFκB ([@b0155]).

It has been shown that the controlled administration of O~3~ may promote an oxidative preconditioning or adaptation to oxidative stress that in turn stimulates the antioxidant endogenous systems resulting in the protection against tissue damage ([@b0005]). However, the exact mechanisms underlying preconditioning are not fully understood. NFκB is a major regulator of inflammations in mammalian cells ([@b0275]). NFκB includes subunits such as NFκB1 (p50/p105), NFκB2 (p52/p100), RelA (p65), RelB, c-Rel and regulates inflammatory and immune responses, cell proliferation or cell death ([@b0200], [@b0140]). Activation of NFκB seems to be a positive regulator of cell growth and an inhibitor of apoptosis in fibroblasts like synoviocytes ([@b0275]). On the contrary, some studies have shown that NFκB activation may promote apoptosis of neural cells ([@b0105]). Inhibition of NFκB activation prevents cell death by apoptosis in human cultured thymocytes ([@b0020]). The functions of NFκB in whether a cell should undergo cell proliferation or apoptosis seem to be cell type dependent. O~3~ inhibition of NFκB activation may cause a reduction in inflammation and apoptotic cell death ([Fig. 3](#f0015){ref-type="fig"}). ROS can activate NFκB directly or through other stimuli such as TNF-α ([@b0055]). In OA, ROS activates NFκB pathways by increasing its translocation into the nuclei and this causes the release of proinflammatory cytokines such as IL-1β, IL-6, TNF-α and COX-2. These cytokines inhibit the synthesis of aggrecan and collagen type II, which are the major components of the cartilage matrix ([@b0250], [@b0100]). In addition, these cytokines increase the release of matrix metalloproteinases and aggrecanase, enzymes that degrade the matrices, causing cartilage damage, disturbance of the metabolic balance of the cartilage matrix and eventually apoptosis ([@b0160]). IL-1β and TNF-α can induce chondrocytes apoptosis by promoting the production of other proinflammatory factors such as prostaglandin E2 (PGE2) and NO ([@b0170]). O~3~ therapy can block the activation of NFκB and therefore inhibiting the release of proinflammatory cytokines. This inhibits the degradation of the cartilage matrix and initiation of the apoptotic pathway, thereby causing cell survival and proliferation. O~3~ can stimulate the production of adenosine triphosphate (ATP) through the glycolysis enzymatic pathway and increase oxygenation to injured cells and thus prevent cell death ([@b0120]).Figure 3Proposed mechanisms of action of ozone (O~3~) therapy in osteoarthritis (OA). ROS formed during OA activates NFκB pathways by increasing its translocation into the nuclei and this causes the activation of intracellular inflammation pathways such as IL-1β, IL-6, TNF-α and COX-2 which then open the apoptotic cascade. O~3~ can inhibit apoptosis and degradation of the cartilage matrix by inhibiting the activation NFκB resulting in cell survival.

6. Conclusion {#s0055}
=============

Once articular cartilage is damaged, it has limited potential to repair itself. Many treatment modalities that are used to repair damaged articular cartilage show limited efficiency. O~3~ therapy is an efficient therapy in the treatment of damaged articular cartilage in OA. O~3~ inhibits the inflammatory milieu which damages the cartilage matrix and induces apoptosis of chondrocytes in OA. It produces its beneficial effects by normalizing the cellular redox balance and through the actions of cytokines. Further *in vitro* studies are required in order to understand the exact mechanisms involved in the stimulation of cells by O~3~.
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